Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides for Telomere Lengthening: Evidence Comparison

Epithalamin Pineal extract; TERT upregulation 33.4% telomere length increase in elderly patients (12 months) Limited Russian trials; no large Western RCTs Research use only; not commercially available Strongest published human data for telomere lengthening, bu

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Epithalamin
  • Pineal extract; TERT upregulation
  • 33.4% telomere length increase in elderly patients (12 months)
  • Limited Russian trials; no large Western RCTs
  • Research use only; not commercially available
  • Strongest published human data for telomere lengthening, but replication needed
  • Epitalon
  • Synthetic Ala-Glu-Asp-Gly; TERT gene expression
  • Telomerase restoration in senescent mice; modest CD4+ telomere gains in small human trial
  • One published human study (n=26); primarily animal data
  • Research peptide; unregulated
  • Promising animal data, insufficient human evidence for definitive claims
  • Thymalin
  • Thymic peptide complex; oxidative stress reduction
  • 2.8-fold telomerase increase in fibroblasts; reduced telomere shortening in lymphocytes
  • Multiple Russian gerontology trials; no FDA-recognised studies
  • Research use; not FDA-approved
  • Strong evidence for immune cell telomere preservation; mechanism indirect
  • MK-677
  • GH secretagogue; IGF-1 elevation
  • No direct telomerase activity demonstrated
  • No telomere-focused trials published
  • Research peptide (not approved for human use)
  • IGF-1 effects theoretically beneficial but telomere link unproven
  • Hexarelin
  • GHRP; GH pulse stimulation
  • No direct telomerase activity
  • No telomere trials
  • Research peptide
  • Same limitations as MK-677; indirect pathway assumptions lack evidence